8-K: Aquestive Therapeutics Stockholders Elect Directors, Approve Executive Pay, and Ratify Auditors at 2025 Annual Meeting

Aquestive Therapeutics, Inc. announced the successful election of two Class I directors, the approval of executive compensation, and the ratification of KPMG LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Summary

• Aquestive Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 11, 2025.
• Daniel Barber and Timothy E. Morris were elected as Class I members of the Board of Directors, each to serve a three-year term until the Company's 2028 Annual Meeting of Stockholders.
• Daniel Barber received 36,060,882 votes For and 3,546,668 votes Against.
• Timothy E. Morris received 35,562,599 votes For and 4,044,951 votes Against.
• The non-binding advisory proposal to approve executive compensation was approved with 32,454,278 votes For, 6,694,084 votes Against, and 459,188 votes Abstaining.
• The appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 66,530,646 votes For, 1,166,766 votes Against, and 1,758,250 votes Abstaining.

Sentiment

Score: 8

Explanation: The sentiment is positive as all proposals presented at the annual meeting were approved by stockholders with strong majorities, indicating stability and alignment in corporate governance.

Positives

• All proposed director nominees, Daniel Barber and Timothy E. Morris, were successfully elected with strong majority support.
• Executive compensation received advisory approval, indicating stockholder confidence in the current compensation structure.
• The appointment of KPMG LLP as the independent auditor was overwhelmingly ratified, demonstrating strong stockholder alignment on financial oversight.

Future Outlook

The document does not provide specific forward-looking statements or financial guidance beyond the term of elected directors and ratified auditor.

Industry Context

This filing is a routine corporate governance update for Aquestive Therapeutics, Inc., detailing the outcomes of its annual stockholder meeting. It does not provide specific insights into broader industry trends or competitive landscape, focusing solely on internal governance matters.

Corporate Governance

Stakeholder Impact

• Shareholders: The election of directors and approval of executive compensation directly impacts corporate governance and oversight, potentially influencing long-term shareholder value. The ratification of the auditor provides assurance regarding financial reporting integrity.
• Management: The approval of executive compensation validates the current compensation strategy and provides clarity for the upcoming year.

Next Steps

• The elected Class I directors, Daniel Barber and Timothy E. Morris, will serve their three-year terms until the 2028 Annual Meeting of Stockholders.
• KPMG LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Annual Meeting, Stockholders, Board of Directors, Director Election, Executive Compensation, Auditor Ratification, KPMG LLP, Corporate Governance, SEC Filing, 8-K